# Targeted Radiotherapy in Androgen-suppressed Prostate Cancer Patients.

> **NCT03644303** · NA · COMPLETED · sponsor: **Royal Marsden NHS Foundation Trust** · enrollment: 86 (actual)

## Conditions studied

- Prostate Cancer
- Metastasis
- Toxicity Due to Radiotherapy
- Circulating Tumour DNA

## Interventions

- **RADIATION:** SBRT + ADT

## Key facts

- **NCT ID:** NCT03644303
- **Lead sponsor:** Royal Marsden NHS Foundation Trust
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-08-13
- **Primary completion:** 2025-03-31
- **Final completion:** 2025-03-31
- **Target enrollment:** 86 (ACTUAL)
- **Last updated:** 2026-05-14

## Collaborators

- Prostate Cancer UK
- University College, London
- The Christie NHS Foundation Trust
- The Leeds Teaching Hospitals NHS Trust
- Velindre NHS Trust
- University Hospital Birmingham NHS Foundation Trust
- Newcastle-upon-Tyne Hospitals NHS Trust
- Belfast Health and Social Care Trust

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03644303

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03644303, "Targeted Radiotherapy in Androgen-suppressed Prostate Cancer Patients.". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT03644303. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*